{"id":"NCT00505778","sponsor":"Warner Chilcott","briefTitle":"A Comparison of Once a Day Dose Compared to 2 Doses/Day","officialTitle":"A Multi-center, Investigator-blinded, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Efficacy of 1.6 to 2.4 g AsacolÂ® Therapy QD Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2009-07","completion":"2009-07","firstPosted":"2007-07-23","resultsPosted":"2011-05-12","lastUpdate":"2013-04-22"},"enrollment":1027,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"Mesalamine Once-Daily","otherNames":["Asacol QD"]},{"type":"DRUG","name":"Mesalamine Twice-Daily","otherNames":["Asacol BID"]}],"arms":[{"label":"Mesalamine (Asacol) Once-Daily","type":"ACTIVE_COMPARATOR"},{"label":"Mesalamine (Asacol) Twice-Daily","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy in maintaining remission of ulcerative colitis between a once daily (QD) Asacol regimen and a divided, twice daily (BID) Asacol dosing regimen.","primaryOutcome":{"measure":"Percentage of Patients Remaining in Remission at Month 6, ITT Population, Determined by the Simple Clinical Colitis Activity Index (SCCAI)","timeFrame":"6 months","effectByArm":[{"arm":"Mesalamine Once-Daily","deltaMin":90.5,"sd":null},{"arm":"Mesalamine Twice-Daily","deltaMin":91.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5016"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":245,"countries":["United States","Canada","Puerto Rico"]},"refs":{"pmids":["20064514"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":512},"commonTop":[]}}